0001708138-20-000012.txt : 20200226 0001708138-20-000012.hdr.sgml : 20200226 20200226181457 ACCESSION NUMBER: 0001708138-20-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Landry Robert E CENTRAL INDEX KEY: 0001585160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20657663 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-02-24 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001585160 Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP Finance CFO Common Stock 2020-02-24 4 M 0 1000 272.7 A 25973 D Common Stock 2020-02-24 4 F 0 786 406.59 D 25187 D Common Stock 2020-02-25 4 M 0 1000 272.7 A 26187 D Common Stock 2020-02-25 4 F 0 800 447.3 D 25387 D Common Stock 2020-02-25 4 S 0 10 438.0 D 25377 D Common Stock 2020-02-25 4 S 0 12 444.03 D 25365 D Common Stock 2020-02-25 4 S 0 11 445.35 D 25354 D Common Stock 2020-02-25 4 S 0 37 447.11 D 25317 D Common Stock 2020-02-25 4 S 0 18 448.54 D 25299 D Common Stock 2020-02-25 4 S 0 54 449.5 D 25245 D Common Stock 2020-02-25 4 S 0 35 450.8 D 25210 D Common Stock 2020-02-25 4 S 0 16 453.6 D 25194 D Common Stock 2020-02-25 4 S 0 4 454.67 D 25190 D Common Stock 2020-02-25 4 S 0 17 455.13 D 25173 D Common Stock 2020-02-26 4 S 0 10 452.04 D 25163 D Common Stock 2020-02-26 4 S 0 44 453.36 D 25119 D Common Stock 2020-02-26 4 S 0 18 454.85 D 25101 D Common Stock 2020-02-26 4 S 0 32 455.37 D 25069 D Common Stock 2020-02-26 4 S 0 10 456.67 D 25059 D Common Stock 2020-02-26 4 S 0 25 457.23 D 25034 D Common Stock 2020-02-26 4 S 0 27 458.35 D 25007 D Common Stock 2020-02-26 4 S 0 34 460.05 D 24973 D Common Stock 172 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 272.7 2020-02-24 4 M 0 1000 0.0 D 2023-09-09 Common Stock 1000 55500 D Non-Qualified Stock Option (right to buy) 272.7 2020-02-25 4 M 0 1000 0.0 D 2023-09-09 Common Stock 1000 54500 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 37 shares of Company stock on February 25, 2020 at prices ranging from $447.00 to $447.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Represents volume-weighted average price of sales of 54 shares of Company stock on February 25, 2020 at prices ranging from $449.01 to $449.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Represents volume-weighted average price of sales of 35 shares of Company stock on February 25, 2020 at prices ranging from $450.70 to $450.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price. Represents volume-weighted average price of sales of 44 shares of Company stock on February 26, 2020 at prices ranging from $453.04 to $453.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 32 shares of Company stock on February 26, 2020 at prices ranging from $455.24 to $455.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 25 shares of Company stock on February 26, 2020 at prices ranging from $457.10 to $457.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 27 shares of Company stock on February 26, 2020 at prices ranging from $458.11 to $458.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 34 shares of Company stock on February 26, 2020 at prices ranging from $460.03 to $460.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. The stock option award vests in four equal annual installments, commencing one year after the date of grant. /s/**Robert E. Landry 2020-02-26